APA

Zeidan A. M., Sekeres M. A., Garcia-Manero G., Steensma D. P., Zell K., Barnard J., Ali N. A., Zimmerman C., Roboz G., DeZern A., Nazha A., Jabbour E., Kantarjian H., Gore S. D., Maciejewski J. P., List A. & Komrokji R. (20160719). Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. : Leukemia.

Chicago

Zeidan A M, Sekeres M A, Garcia-Manero G, Steensma D P, Zell K, Barnard J, Ali N A, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore S D, Maciejewski J P, List A and Komrokji R. 20160719. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. : Leukemia.

Harvard

Zeidan A. M., Sekeres M. A., Garcia-Manero G., Steensma D. P., Zell K., Barnard J., Ali N. A., Zimmerman C., Roboz G., DeZern A., Nazha A., Jabbour E., Kantarjian H., Gore S. D., Maciejewski J. P., List A. and Komrokji R. (20160719). Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. : Leukemia.

MLA

Zeidan A M, Sekeres M A, Garcia-Manero G, Steensma D P, Zell K, Barnard J, Ali N A, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore S D, Maciejewski J P, List A and Komrokji R. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. : Leukemia. 20160719.